180 related articles for article (PubMed ID: 15601813)
1. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Longee D
Pediatrics; 2005 Jan; 115(1):e115-9. PubMed ID: 15601813
[TBL] [Abstract][Full Text] [Related]
2. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
3. B cell depletion therapy for new-onset opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
[TBL] [Abstract][Full Text] [Related]
4. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
5. [Opsoclonus myoclonus ataxia syndrome in Israel].
Blumkin L; Lerman-Sagie T
Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
7. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
8. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.
Bell J; Moran C; Blatt J
Pediatr Blood Cancer; 2008 Feb; 50(2):370-1. PubMed ID: 16652344
[TBL] [Abstract][Full Text] [Related]
9. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
Leen WG; Weemaes CM; Verbeek MM; Willemsen MA; Rotteveel JJ
Pediatr Neurol; 2008 Sep; 39(3):213-7. PubMed ID: 18725071
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
11. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes.
Pranzatelli MR; Travelstead AL; Tate ED; Allison TJ; Moticka EJ; Franz DN; Nigro MA; Parke JT; Stumpf DA; Verhulst SJ
Neurology; 2004 May; 62(9):1526-32. PubMed ID: 15136676
[TBL] [Abstract][Full Text] [Related]
12. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in autoimmune diseases.
Virgolini L; Marzocchi V
Biomed Pharmacother; 2004 Jun; 58(5):299-309. PubMed ID: 15194166
[TBL] [Abstract][Full Text] [Related]
14. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus.
Pranzatelli MR; Tate ED; Travelstead AL; Colliver JA
J Clin Immunol; 2010 Jan; 30(1):106-13. PubMed ID: 19838774
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
Rao A; Kelly M; Musselman M; Ramadas J; Wilson D; Grossman W; Shenoy S
Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702
[TBL] [Abstract][Full Text] [Related]
16. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
[TBL] [Abstract][Full Text] [Related]
17. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
Burke MJ; Cohn SL
Pediatr Blood Cancer; 2008 Mar; 50(3):679-80. PubMed ID: 16900484
[TBL] [Abstract][Full Text] [Related]
19. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
Stübgen JP
J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
Pranzatelli MR; Tate ED
Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
